Tagged with R

Allergan How have PBS reforms impacted Allergan in Australia? The PBS is a very good system that provides Australians with equity of access and has worked well in the country for many years. Once a therapeutic is approved and funded, Australia has one of the highest penetration rates around the world.…

Alphapharm Alphapharm recently celebrated its 25th anniversary. In light of this significant milestone, would you give us a brief introduction to the company? Alphapharm started in 1982 in Brisbane with a handful of products and a handful of people. Twenty-five years later, we celebrated our silver anniversary, coming from nowhere to…

Sanofi Australia What impact have the PBS reforms had on sanofi-aventis in Australia? Sanofi-aventis has one of the largest portfolios of medicines in Australia, with over 240 products in the key areas of cardiometabolic disease, thrombosis, oncology, vaccines, CNS, and internal medicine. The PBS reforms clearly are the major reforms over the…

Pretium Australia Would you please introduce Pretium’s specific service offerings, and the focus within these? Pretium offers a comprehensive range of integrated services across our 4 lines of business – Market Intelligence, Health Economics, Late Phase Research and Disease Management. The distinction between the various stages of a product’s life cycle and…

Commercial Eyes What are some of the challenges facing pharmaceutical companies in Australia today? There are four major challenges within the Australian pharmaceutical industry at the moment. The increasing complexity of getting a medicine registered; getting a product reimbursed via the Pharmaceutical Benefits Scheme (PBS); dealing with the challenges of PBS reforms;…

Galderma As ASMI President and Managing Director of Galderma, would you please give us a brief overview of the Australian OTC market and Galderma’s role therein? Galderma is a leading player in the worldwide dermatology market formed in 1981 as a L’Oreal-Nestle joint venture. Its aspirations are reflected in its commitment…

Amgen Australia What impact have the PBS reforms had on Amgen in Australia? From a company perspective, biotechnology companies exist in a competitive space. They have predominantly niche medicines with significant competitive advantages and tend to be on their own in a certain clinical space and treatment paradigm. Amgen sells very few…

Pharmaceutical Industry Council (PIC) 2006 marked a major milestone, with the Pharmaceutical Industry Action Agenda transformed from a Government-industry initiative into an industry-driven agenda, and the resulting creation of the Pharmaceutical Industry Council (PIC). Would you please introduce the organization, and tell us about the main milestones and achievements since you began your tenure…

Novotech (Australia) Pty Limited One of the hot topics in the industry is the impact of PBS reforms. Can you speak to recent influence of PBS reforms affecting Novotech’s services in Australia? In our particular business, there is very minimal effect. Because Novotech is a service company, most of its clients are engaged in…

UTI Pharma South Africa We interviewed Graham Somerville in 2004, the year when IHD, formerly jointly owned by 11 major pharmaceutical companies, was acquired by UTi. We are interviewing you today at the head of a much bigger company. To what extent has the distributor now taken a new dimension in terms of financials,…

Medicines Australia To begin, would you please introduce Medicines Australia to Pharmaceutical Executive readers? Medicines Australia is the association that represents the country’s research-based pharmaceutical industry. With approximately 50 members, the organization comprises all major innovator companies, consisting of the significant American and European pharmaceutical players, in addition to some Australian companies…

SERVIER Laboratories (Australia) Pty Ltd Servier was eligible to receive $7 million in P3 funding; can you tell us how this initiative has helped the company? P3 was not one of the main reasons why Servier has invested more in Australia of late. What drives Servier’s headquarters to conduct more research in Australia is a…